| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3354381 | Immunity | 2006 | 6 Pages |
Abstract
After a very long and windy road, in December of 2005 the FDA approved CTLA4Ig for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jeffrey A. Bluestone, E. William St. Clair, Laurence A. Turka,